[
  {
    "ts": "2026-03-01T22:08:31+00:00",
    "headline": "Regeneron’s Dupixent Win And Rare Disease Push Reshape Risk Reward Profile",
    "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis in both adults and children. The FDA also accepted garetosmab for Priority Review in adults with fibrodysplasia ossificans progressiva, an ultra rare genetic disorder. These two decisions highlight how Regeneron is pushing deeper into both common and rare disease categories at the same time. With the share price at $781.67 and a 5 yr return of 70.5%,...",
    "url": "https://finance.yahoo.com/news/regeneron-dupixent-win-rare-disease-220831250.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "51f54c0b-3e70-3a50-8464-da1cd83ac813",
      "content": {
        "id": "51f54c0b-3e70-3a50-8464-da1cd83ac813",
        "contentType": "STORY",
        "title": "Regeneron’s Dupixent Win And Rare Disease Push Reshape Risk Reward Profile",
        "description": "",
        "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis in both adults and children. The FDA also accepted garetosmab for Priority Review in adults with fibrodysplasia ossificans progressiva, an ultra rare genetic disorder. These two decisions highlight how Regeneron is pushing deeper into both common and rare disease categories at the same time. With the share price at $781.67 and a 5 yr return of 70.5%,...",
        "pubDate": "2026-03-01T22:08:31Z",
        "displayTime": "2026-03-01T22:08:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w30LARiR1Z35GusfaFi.2g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3eDp_RSETU8kXm3usDK_gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-dupixent-win-rare-disease-220831250.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-dupixent-win-rare-disease-220831250.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]